Propentofylline and iloprost suppress the production of TNF-α by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in lewis rats

Journal of Autoimmunity

Volumn 10, Issue 6, 1997, Pages 519-529

  Jung, Stefan ^a   Donhauser, Torsten ^a   Toyka, Klaus V ^a   Hartung, Hans Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

EAE; Multiple sclerosis; Phosphodiesterase; Prostaglandin TNF

Indexed keywords

ILOPROST; PROPENTOFYLLINE; TUMOR NECROSIS FACTOR;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CENTRAL NERVOUS SYSTEM; EFFECTOR CELL; ENZYME INHIBITION; HELPER CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MACROPHAGE ACTIVATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031439078     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1997.0159     Document Type: Article

References (53)

1. Swanborg R.H. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathol. 77:1995;4-13.
2. Raine C.S. Demyelinating diseases. Textbook of Neuropathology. 1992;Williams and Wilkins, Baltimore.
3. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
4. Hartung H.P., Jung S., Stoll G., Zielasek J., Schmidt B., Archelos J.J., Toyka K.V. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J. Neuroimmunol. 40:1992;197-210.
5. Selmaj K., Papierz W., Glabinski A., Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol. 56:1995;135-141.
6. Hartung H.-P. Pathogenesis of inflammatory demyelination: implications for therapy. Curr. Opin. Neurol. 8:1995;191-199.
7. Moore A.R., Willoughby D.A. The role of cAMP regulation in controlling inflammation. Clin. Exp. Immunol. 101:1995;387-389.
8. Kammer G.A. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today. 9:1988;222-229.
9. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:1990;150-155.
10. Novak T.J., Rothenberg E. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. USA. 87:1990;9353-9357.
11. Thanhauser A., Reiling N., Bohle A., Toellner K.M., Duchrow M., Scheel D., Schluter C., Ernst M., Flad H.D., Ulmer A.J. Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology. 80:1993;151-156.
12. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1993;1745-1751.
13. Han J., Thompson P., Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172:1990;391-394.
14. Sinha B., Semmler J., Eisenhut T., Eigler A., Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur. J. Immunol. 25:1995;147-153.
15. Eisenhut T., Sinha B., Gröttrup-Wolfers E., Semmler J., Siess W., Endres S. Prostacyclin analogs suppress the synthesis of tumor necrosis factor-a in LPS-stimulated human peripheral blood mononuclear cells. Immunopharmacology. 26:1993;259-264.
16. Grundmann H.J., Hahnle U., Hegenscheid B., Sahlmüller G., Bienzle U., Blitstein Willinger E. Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J. Infect. Dis. 165:1992;501-505.
17. 2. J. Immunol. 150:1993;5321-5329.
18. 2. J. Immunol. 146:1991;108-113.
19. Phipps R.P., Stein S.H., Roper R.L. A new view of prostaglandin E regulation of the immune system. Immunol. Today. 12:1991;349-352.
20. Crutchley D.J., Conanan L.B., Que B.G. Effects of prostacyclin analogs on the synthesis of tissue factor, tumor necrosis factor-a and interleukin-1b in human monocytic THP-1 cells. J. Pharmacol. Exp. Ther. 271:1994;446-451.
21. van der Pouw Kraan T.C.T.M., Boeije L.C.M., Smeenk R.J.T., Wijdenes J., Aarden L.A. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J. Exp. Med. 181:1995;775-779.
22. Jung S., Zielasek J., Köllner G., Donhauser T., Toyka K., Hartung H.-P. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68:1996;1-11.
23. Sommer N., Löschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmüller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med. 1:1995;244-248.
24. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 46:1991;512-523.
25. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., Polson J.B. Multiple high-affinity cAMP phosphodiesterases in human T-lymphocytes. Biochem. Pharmacol. 42:1991;869-877.
26. Ichimura M., Kase H. A new cyclic nucleotide phosphodiesterase isoenzyme expressed in the T-lymphocyte cell lines. Biochem. Biophys. Res. Commun. 193:1993;985-990.
27. Meskini N., Nemoz G., Okyayuz Baklouti I., Lagarde M., Prigent A.F. Phosphodiesterases inhibitory profile of some related xanthine derivatives pharmacologically active on the peripheral microcirculation. Biochem. Pharmacol. 47:1994;781-788.
28. 2. Naunyn-Schmiedeberg's Arch. Pharmacol. 316:1981;252-256.
29. Eylar E.H., Kniskern P.J., Jackson J.J. Myelin basic proteins. Methods Enzymol. 32:1971;323-341.
30. Jung S., Toyka K., Hartung H.P. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur. J. Immunol. 25:1995;1391-1398.
31. Jung S., Toyka K.V., Hartung H.-P. Impact of 15-deoxyspergualin on effector cells in experimental autoimmune diseases of the nervous system in the Lewis rat. Clin. Exp. Immunol. 98:1994;494-502.
32. Nataf S., Louboutin J.P., Chabannes D., Feve J.R., Muller J.Y. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol. Scand. 88:1993;97-99.
33. DeLeo J., Schubert P., Kreutzberg G.W. Protection against ischemic brain damage using propentofylline in gerbils. Stroke. 19:1988;1535-1539.
34. Dux E., Fastbom J., Ungerstedt U., Rudolphi K., Fredholm B.B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res. 516:1990;248-256.
35. Sliwa K., Grundmann H.J., Neifer S., Chaves M.F., Sahlmueller G., Blitstein-Willinger E., Bienzle U., Kremsner P.G. Prevention of murine cerebral malaria by a stable prostacyclin analog. Infect. Immun. 59:1991;3846-3848.
36. 1. Clin. Exp. Immunol. 99:1995;454-460.
37. 1. J. Clin. Invest. 79:1987;782-789.
38. Tsuboi Y., Shankland S.S., Grande J.P., Walker H.J., Johnson R.J., Dousa T.P. Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isoenzymes types III and IV. J. Clin. Invest. 98:1996;262-270.
39. 1. Surgery. 98:1985;45-53.
40. Reder A.T., Thapar M., Sapugay A.M., Jensen M.A. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental autoimmune encephalomyelitis. J. Neuroimmunol. 54:1994;117-127.
41. Huitinga I., Van Rooijen N., de Groot C.J.A., Uitdehaag B.M.J., Dijkstra C.D. Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. 172:1990;1025-1033.
42. Rowles J.R., Foegh M.L., Khirabadi B.S., Ramwell P.W. The synergistic effect of cyclosporine and iloprost on survival of rat cardiac allografts. Transplantation. 42:1986;94-96.
43. Filipponi F., Michel A., Houssin D. Prolongation of guinea pig-to-rat xenograft survival with BN 52063, a specific antagonist of platelet-activating factor. Ital. J. Surg. Sci. 19:1989;325-329.
44. MacPhee C.H., Reifsnyder D.H., Moore T.A., Lerea K.M., Beavo J.A. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J. Biol. Chem. 263:1988;10353-10358.
45. 2. Inflammation. 5:1981;81-87.
46. Valitutti S., Dessing M., Lanzavecchia A. Role of cAMP in regulating cytotoxic T lymphocyte adhesion and motility. Eur. J. Immunol. 23:1993;790-795.
47. 2. J. Immunol. 152:1994;5703-5713.
48. Lidington E., Nöhammer C., Dominguez M., Ferry B., Rose M.L. Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin. Exp. Immunol. 104:1996;66-71.
49. Derian C.K., Santulli R.J., Rao P.E., Solomon H.F., Barrett J.A. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators. J. Immunol. 154:1995;308-317.
50. Griswold D.E., Webb E.F., Breton J., White J.R., Marshall P.J., Torphy T.J. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response. Inflammation. 17:1993;333-344.
51. 42. Clin. Exp. Immunol. 81:1990;160-165.
52. Pober J.S., Slowik M.R., De Luca L.G., Ritchie A.J. Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1. J. Immunol. 150:1993;5114-5123.
53. Suttorp N., Weber U., Welsch T., Schudt C. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J. Clin. Invest. 91:1993;1421-1428.